Adamas publishes results of Phase 3 EASE LID clinical trial of ADS-5102
Adamas Pharmaceuticals announced that results of its Phase 3 EASE LID clinical trial of ADS-5102 were published online in JAMA Neurology. A New Drug Application supporting ADS-5102 extended-release capsules for the treatment of levodopa-induced dyskinesia in people with Parkinson's disease is under review by the FDA with a PDUFA action date of August 24. If approved, ADS-5102 will be the first and only medicine indicated for the treatment of LID in people with Parkinson's disease. The placebo-controlled Phase 3 trial demonstrated that ADS-5102 significantly reduced both Dyskinesia and OFF Time at six months in Parkinson's disease patients with Levodopa-induced Dyskinesia.